Galderma and Sofregen Medical have signed a co-development and option-to-acquire agreement. The collaboration will expand Galderma’s work on biostimulator and hyaluronic acid (HA) fillers and Softregen's silk technology. Sofregen’s silk technology combines silk protein with an hyaluronic acid carrier, as silk has been shown to have unique properties for tissue support and regeneration. The companies will work and co-develop activities related to silk-based biostimulator fillers. They plan to launch the development programs for all products as soon as possible. Galderma will have an exclusive option to acquire Sofregen’s Silk Voice, and would grant Galderma all rights to the products being co-developed by the parties, including ownership of Sofregen’s silk technology platform in the aesthetic and dermatological field. “At Galderma, we’re committed to advancing dermatology through constant innovation and joining forces with other industry pioneers," says Baldo Scassellati Sforzolini, Global Head of Research and development at Galderma. "Combining Galderma’s capabilities and scale with Sofregen’s novel silk platform represents a watershed moment for the aesthetics market through the development of a new category of biostimulator fillers designed to make an impact for healthcare professionals and their patients.”
Related Articles
Galderma Receives FDA Approval for Cheek Fillers
Galderma Launches Webinar Series About Impact of Wearing a Mask